Download PDF
Semin Thromb Hemost 2002; 28(2): 149-160
DOI: 10.1055/s-2002-27817
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Comparative Study on Collagen-Binding Enzyme-Linked Immunosorbent Assay and Ristocetin Cofactor Activity Assays for Detection of Functional Activity of von Willebrand Factor

Peter L. Turecek, Jürgen Siekmann, Hans Peter Schwarz
  • Baxter Bioscience, Vienna, Austria
Further Information

Publication History

Publication Date:
03 May 2002 (online)

    Permissions and Reprints

ABSTRACT

For more than two decades, the ristocetin cofactor (RCo) assay, which measures the von Willebrand factor (vWF)-mediated agglutination of platelets in the presence of the antibiotic ristocetin, has been the most common method for measuring the functional activity of vWF. There is, however, general agreement among clinical analysts that this method has major practical disadvantages in performance and reproducibility. Today, collagen-binding assays (CBA) based on the enzyme-linked immunosorbent assay (ELISA) technique that measure the interaction of vWF and collagen are an alternative analytic procedure based on a more physiological function than that of the RCo procedure. We used both assay systems in a comparative study to assess the functional activity of vWF in plasma as well as in therapeutic preparations. We measured RCo activities of plasma from healthy donors and patients with different types of von Willebrand disease (vWD) and of vWF as a drug substance in factor (F) VIII/vWF concentrates using both the aggregometric and the macroscopic methods. In addition, we measured collagen-binding activity (vWF:CB) using a recently developed commercially available CBA system. To investigate the relation between the structure and the functional activity of vWF, we isolated vWF species with different numbers of multimers from FVIII/vWF concentrates by affinity chromatography on immobilized heparin. The vWF:RCo and vWF:CB of the different fractions were measured, and the multimeric structure of vWF was analyzed by sodium dodecyl sulfate (SDS) agarose gel electrophoresis. (vWF:CB and vWF:RCo are part of the nomenclature proposed by the International Society on Thrombosis and Hemostasis Scientific and Standardization Committee [ISTH SSC] subcommittee on von Willebrand factor, in Maastricht, Germany, June 16, 2000.) Measurement of functional vWF activity by CBA can be carried out with substantially higher interassay reproducibility than can measurement of RCo. Both assay systems can be used for diagnosis and subtyping of vWD, but CBA is more sensitive than either of the two RCo methods. The analysis of vWF multimers in the different fractions obtained by affinity chromatography on heparin Sepharose showed that the activity measured both with RCo assay and CBA correlated with the degree of multimerization. Our results suggest that measurement of the functional activity of vWF by the RCo procedure can be replaced by the more reliable CBA, reflecting the physiological hemostatic activity of vWF. The CBA method appears not only to be more sensitive and easier to carry out than the RCo method is but also to have a higher reproducibility and allow better standardization.

KEYWORDS

von Willebrand factor - vWF - ristocetin cofactor activity - collagen-binding activity - FVIII/vWF concentrates - von Willebrand disease - heparin affinity chromatography

REFERENCES

  • 1 Ruggeri Z M. Structure and function of von Willebrand factor.  Thromb Haemost . 1999;  82 576-584
    PubMedGoogle Scholar
  • 2 Sadler J E. Biochemistry and genetics of von Willebrand factor.  Annu Rev Biochem . 1998;  67 395-424
    CrossrefPubMedGoogle Scholar
  • 3 Girma J P, Ribba A S, Meyer D. Structure-function relationship of the A1 domain of von Willebrand factor.  Thromb Haemost . 1995;  74 156-160
    PubMedGoogle Scholar
  • 4 Fowler W E, Fretto L J, Hamilton K K, Erickson H P, McKee P A. Substructure of human von Willebrand factor.  J Clin Invest . 1985;  76 1491-1500
    CrossrefPubMedGoogle Scholar
  • 5 Furlan M, Robles R, Affolter D. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.  Proc Natl Acad Sci USA . 1993;  90 7503-7507
    PubMedGoogle Scholar
  • 6 Fischer B E, Thomas K B, Schlokat U, Dorner F. Triplet structure of human von Willebrand factor.  Biochem J . 1998;  331(part 2) 483-488
    PubMedGoogle Scholar
  • 7 Sobel M, Soler D F, Kermode J C, Harris R B. Localization of a heparin binding domain peptide of human von Willebrand factor.  J Biol Chem . 1992;  267 8857-8862
    PubMedGoogle Scholar
  • 8 Kroner P A, Frey A B. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine scanning mutagenesis.  Biochemistry . 1996;  35 13460-13468
    CrossrefPubMedGoogle Scholar
  • 9 DeLuca M, Facey D A, Favaloro E J. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.  Blood . 2000;  95 164-172
    PubMedGoogle Scholar
  • 10 Sadler J E, Matsushita T, Dong Z, Tuley E A, Westfield L A. Molecular mechanism and classification of von Willebrand disease.  Thromb Haemost . 1995;  74 161-166
    PubMedGoogle Scholar
  • 11 Weiss H J, Hoyer L W, Rickles F R, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation.  J Clin Invest . 1973;  52 2708-2716
    CrossrefPubMedGoogle Scholar
  • 12 MacFarlane D E, Stibbe J, Kirby E P. A method for assaying von Willebrand factor (ristocetin cofactor).  Thrombosis et Diathesis Haemorrhagica . 1975;  34 306-308
    PubMedGoogle Scholar
  • 13 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.  Thromb Haemost . 2000;  83 107-113
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Brown J E, Bosak J O. An ELISA test for the binding of von Willebrand factor antigen to collagen.  Thromb Res . 1986;  43 303-311
    CrossrefPubMedGoogle Scholar
  • 15 Favaloro E J, Grispo L, Exner T, Koutts J. Development of a single collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease.  Blood Coagul Fibrinolysis . 1991;  2 285-291
    CrossrefPubMedGoogle Scholar
  • 16 Siekmann J, Turecek P L, Schwarz H P. The determination of von Willebrand factor activity by collagen binding assay.  Haemophilia . 1998;  4(Suppl 3) 15-24
    PubMedGoogle Scholar
  • 17 Fehlner J R, Hutchinson R EJ, Tarbell D S, Schenck J R. Structure of ristocetin A.  Proc Natl Acad Sci USA . 1972;  69 2420-2421
    PubMedGoogle Scholar
  • 18 Williams D H, Rajajanda V, Kalman J R. On the structure and mode of action of the antibiotic ristocetin A.  J Chem Soc Perkin I . 1979;  3 787-792
    PubMedGoogle Scholar
  • 19 Waltho J P, Williams D H. Aspects of molecular recognition: solvent exclusion and dimerization of the antibiotic ristocetin when bound to a model bacterial cell-wall precursor.  J Am Chem Soc . 1989;  111 2475-2480
    CrossrefPubMedGoogle Scholar
  • 20 Bardsley B, Williams D H, Baglin T P. Cleavage of rhamnose from ristocetin A removes its ability to induce platelet aggregation.  Blood Coagul Fibrinolysis . 1998;  9 241-244
    PubMedGoogle Scholar
  • 21 Perkins H R, Nieto M. The chemical basis for the action of the vancomycin group of antibiotics.  Ann NY Acad Sci . 1974;  235 348-363
    PubMedGoogle Scholar
  • 22 Gangarosa E J, Johnson T R, Ramos H S. Ristocetin-induced thrombocytopenia; site and mechanism of action.  Arch Intern Med . 1960;  105 83-89
    PubMedGoogle Scholar
  • 23 Howard M A, Firkin B G. Ristocetin-a new tool in the investigation of platelet aggregation.  Thrombosis et Diathesis Haemorrhagica . 1971;  26 362-369
    PubMedGoogle Scholar
  • 24 Howard M A, Sawers R J, Firkin B G. Ristocetin: a means of differentiating von Willebrand's disease into two groups.  Blood . 1973;  41 687-690
    CrossrefPubMedGoogle Scholar
  • 25 Brinkhous K M, Read M S. Fixation platelets and platelet agglutination aggregation tests.  Methods Enzymol . 1989 (part A);  169 149-163
    PubMedGoogle Scholar
  • 26 Puri S, Gresham C, Kao K J. A simple quantitative assay for ristocetin cofactor activity using microtiter plate and ELISA plate reader.  Thromb Res . 1994;  74 285-291
    CrossrefPubMedGoogle Scholar
  • 27 Engelhardt W, Patzke J, Pelzer H. Von Willebrand ristocetin cofactor: fast and precise determination on coagulation analyzers.  Ann Hematol (Abst) . 1999;  78(Suppl I) A74
    PubMedGoogle Scholar
  • 28 Jenkins C SP, Meyer D, Dreyfus M D, Larrieu M J. Willebrand and ristocetin. I. Mechanism of ristocetin-induced platelet aggregation.  Br J Haematol . 1974;  28 561-578
    CrossrefPubMedGoogle Scholar
  • 29 Coller B S, Gralnick H R. Studies on the mechanism of ristocetin-induced platelet agglutination.  J Clin Invest . 1977;  60 302-312
    PubMedGoogle Scholar
  • 30 Scott J P, Montgomery R R, Retzinger G S. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets.  J Biol Chem . 1991;  266 8149-8155
    PubMedGoogle Scholar
  • 31 Matsushita T, Sadler J E. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib.  J Biol Chem . 1995;  270 13406-13414
    CrossrefPubMedGoogle Scholar
  • 32 Coller B S. von Willebrand disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice, 2nd ed Philadelphia: Lippincott 1987: 60-96
    Google Scholar
  • 33 Azuma H, Sugimoto M, Ruggeri Z, Ware J. A role for von Willebrand factor proline residues 702- 704 in ristocetin mediated binding to platelet glycoprotein Ib.  Thromb Haemost . 1993;  69 192-196
    PubMedGoogle Scholar
  • 34 Hoylaerts M F, Nuyts K, Peerlinck K, Deckmyn H, Vermylen J. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin.  Biochem J . 1995;  306(part 2) 453-463
    PubMedGoogle Scholar
  • 35 Ewenstein B M. von Willebrand's disease.  Annu Rev Med . 1997;  48 525-542
    CrossrefPubMedGoogle Scholar
  • 36 Favaloro E J, Smith J, Petinos P, Hertzberg M, Koutts J. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficiency by means of a multi-laboratory survey.  Thromb Haemost . 1999;  82 1276-1282
    PubMedGoogle Scholar
  • 37 Barrowcliffe T W, Kemball-Cook G, Morris G. Factor VIII-related activities in therapeutic concentrates.  J Lab Clin Med . 1981;  97 429-438
    PubMedGoogle Scholar
  • 38 Chang P, Aronson D L. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities.  Thromb Haemost . 1997;  78 930-933
    PubMedGoogle Scholar
  • 39 Gilchrist M, Stewart M W, Etches W S, Gordon P A. Rapid diagnosis of von Willebrand's disease using ELISA technology.  Thromb Res . 1990;  57 659-664
    CrossrefPubMedGoogle Scholar
  • 40 Thomas K B, Sutor A H, Zieger B. A simple test for the determination of the von Willebrand factor function: the collagen binding activity.  Hämostaseologie . 1994;  14 133-139
    PubMedGoogle Scholar
  • 41 Favaloro E J. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand's disease (vWD), and discrimination of vWD subtypes, depends on collagen source.  Thromb Haemost . 2000;  83 127-135
    PubMedGoogle Scholar
  • 42 Fitzsimmons C M, Cockburn C G, Hornsey V, Prowse C V, Barnes M J. The interaction of von Willebrand factor (vWF) with collagen: Investigation of vWF-binding sites in the collagen molecule.  Thromb Haemost . 1988;  59 186-192
    PubMedGoogle Scholar
  • 43 Pareti F, Fujimura Y, Dent J. Isolation and characterization of a collagen binding domain in human von Willebrand factor.  J Biol Chem . 1986;  261 15310-15315
    PubMedGoogle Scholar
  • 44 Roth G J, Titani K, Hoyer L W, Hickey M J. Localization of binding sites within human von Willebrand factor for monomeric type III collagen.  Biochemistry . 1986;  25 8357-8361
    CrossrefPubMedGoogle Scholar
  • 45 Miller E J, Gay S. Collagen: An overview and update.  Methods Enzymol . 1987;  144 3-41
    PubMedGoogle Scholar
  • 46 Furuto D K, Miller E J. Isolation and characterization of collagens and procollagens.  Methods Enzymol . 1987;  144 41-61
    PubMedGoogle Scholar
  • 47 Favaloro E J. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects.  Am J Clin Pathol . 2000;  114 608-618
    CrossrefPubMedGoogle Scholar
  • 48 Hillery C A, Manusco D J, Sadler J E. Type 2M von Willebrand disease: F6606I and I662F mutations in the glycoprotein binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.  Blood . 1998;  91 1572-1581
    PubMedGoogle Scholar
  • 49 Ramasamy I, Farrugia A, Tran E, Anastasius V, Charnock A. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.  Biologicals . 1998;  26 155-166
    CrossrefPubMedGoogle Scholar
  • 50 Human coagulation factor VIII, freeze-dried. In: Monography 1998;0275 European Pharmacopoeia, 3rd ed. 1998 (Suppl): 336-337
    Google Scholar
  • 51 Ingerslev J. A sensitive ELISA for von Willebrand factor (vWF:Ag).  Scand J Clin Lab Invest . 1987;  47 143-149
    CrossrefPubMedGoogle Scholar
  • 52 Murdock P J, Woodhams B J, Matthews K B, Pasi K J, Goodall A H. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.  Thromb Haemost . 1997;  78 1272-1277
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Chand S, McCraw A, Hutton R, Tuddenham E GD, Goodall A H. A two-site, monoclonal antibody-based immunoassay for von Willebrand factor-demonstration that vWF function resides in a conformational epitope.  Thromb Haemost . 1986;  555 318-324
    PubMedGoogle Scholar
  • 54 Preston F E. Assays for von Willebrand factor functional activity: A UK NEQAS survey.  Thromb Haemost (Letter) . 1998;  80 863
    PubMedGoogle Scholar
  • 55 Kessels H, Beguin S, Wagenvoord R, Hemker H C. A method for measuring activated factor VIII in plasma.  Thromb Haemost . 1991;  66 430-434
    PubMedGoogle Scholar
  • 56 Evans R J, Austen D EG. Assay of ristocetin co-factor using fixed platelets and a platelet counting technique.  Br J Haematol . 1977;  37 289-294
    PubMedGoogle Scholar
  • 57 Ruggeri Z M, Zimmerman T S. The complex multimeric composition of factor VIII/von Willebrand factor.  Blood . 1981;  57 1140-1143
    PubMedGoogle Scholar
  • 58 Turecek P L, Gritsch H, Pichler L. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.  Blood . 1997;  90 3555-3567
    PubMedGoogle Scholar
  • 59 Aihara M, Sawada Y, Ueno K. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex.  Thromb Haemost . 1986;  55 263-267
    PubMedGoogle Scholar
  • 60 Siekmann J, Turecek P L, Schwarz H P. The hemostatic potency of von Willebrand factor in FVIII/vWF concentrates is reflected by affinity to immobilized heparin.  Ann Hematol (Abst) . 1999;  78(Suppl I) A61
    PubMedGoogle Scholar
  • 61 Wright R D, Krauss J S. A comparison of two macroscopic platelet agglutination assays for von Willebrand factor.  Ann Clin Lab Sci . 1990;  20 73-78
    PubMedGoogle Scholar
  • 62 Favaloro E J, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease.  Pathology . 1997;  29 385-391
    CrossrefPubMedGoogle Scholar
  • 63 De Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu-evidence of the importance of the multimerization degree of vWF.  Thromb Haemost . 1993;  69 436-440
    PubMedGoogle Scholar
  • 64 Fischer B E, Kramer G, Mitterer A. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.  Thromb Res . 1996;  84 55-66
    CrossrefPubMedGoogle Scholar
  • 65 Favaloro E J. Laboratory assessment as a critical component of the appropriate diagnosis and subclassification of von Willebrand's disease.  Blood Rev . 1999;  13 185-204
    CrossrefPubMedGoogle Scholar
  • 66 Dean J A, Blanchette V S, Carcao M D. Von Willebrand disease in a pediatric-based population: Comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.  Thromb Haemost . 2000;  84 401-409
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Rodheghiero F, Castaman G, Meyer D, Mannucci P M. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease.  Vox Sang . 1992;  62 193-199
    PubMedGoogle Scholar
  • 68 Menache D, Aronson D L. New treatments of von Willebrand disease: Plasma-derived von Willebrand factor concentrates.  Thromb Haemost . 1997;  78 566-570
    PubMedGoogle Scholar
  • 69 Auerswald G, Eberspächer B, Kreuz W. Successful treatment of patients with von Willebrand disease using a high purity double virus inactivated FVIII/vWF concentrate (IMMUNATE).  Ann Hematol (Abst) . 2000;  79(Suppl I) A129
    PubMedGoogle Scholar